Investigational drug · Phase 2
KBP-336
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Osteoarthritis in the Knee, Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "KBP-336"
First trial start
2025
Jan 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KBP-336", any sponsor or status.
Conditions studied
As listed on its trial records.
- Osteoarthritis in the Knee
- Obesity
Approved drugs for the same conditions: Obesity and weight management · Osteoarthritis · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "KBP-336" as an intervention, largest first.
- Efficacy and Safety of KBP-336 in Obese Individuals with OsteoarthritisPivotal-lookingRecruiting
KeyBioscience AGIndustry
NCT06833749 · 600 participants (planned) · Start Jan 28, 2025 · Primary completion Nov 2026
Drug: KBP-336; Placebo · For: Osteoarthritis in the Knee; Obesity
Sites: Brno, Czechia; Hlučín, Czechia; Hradiště, Czechia · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- DACRA induces profound weight loss, satiety control, and increased mitochondrial respiratory capacity in adipose tissue.
Petersen EA, Blom I, Melander SA, et al. · Int J Obes (Lond) 2024
- The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes.
Larsen AT, Mohamed KE, Melander SA, et al. · Am J Physiol Endocrinol Metab 2024
- The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection - a novel disease-modifying osteoarthritis drug.
Mohamed KE, Larsen AT, Melander S, et al. · Arthritis Res Ther 2024
- Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight.
Melander SA, Larsen AT, Karsdal MA, et al. · Br J Pharmacol 2024
- The Insulin Sensitizer KBP-336 Prevents Diabetes-Induced Cognitive decline in ZDF Rats.
Larsen AT, Mohamed KE, Petersen EA, et al. · J Prev Alzheimers Dis 2024
- Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss.
Thorsø Larsen A, Karsdal MA, Henriksen K · Eur J Pharmacol 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.